FDA Cites Lupin For Poor Quality Metric Performance
Executive Summary
Indian firm's invalidated out-of-specification rate was too high, FDA suggests in heavily redacted Form 483 report. This rate, which also came up in two recent warning letters, happens to be one of the three rates the USagency wants to use as quality metrics for deciding how soon investigators should revisit sites.
You may also be interested in...
The Quality Lowdown: Alvotech, Lupin, Cipla, Lilly, Rentschler Inspection Findings And Akorn Recall
US FDA finds flawed data integrity, investigations, aseptic practices and more at range of foreign and domestic drug product manufacturing facilities, while a bankruptcy leads to a massive drug recall.
More Change With Less Hoopla To FDA Out-Of-Specification Investigations Policy
Agency’s revised OOS guidance clarifies positions on outlier test results, averaging of HPLC results and some finer points around OOS questions. These could marginally improve compliance but won’t impact industry with nearly the force of the original 2006 guidance or the 1993 court ruling that preceded it.
FDA Warns Apotex Management To Demand Quality, Meet Specs
Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.